Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Dalpiciclib|DRUG: Aromatase inhibitor|DRUG: Docetaxel injection|DRUG: Epirubicin Hydrochloride Injection|DRUG: Cyclophosphamide injection
Sponsor: Hebei Medical University Fourth Hospital